Trajectory of genome editing technology Authors: Yonglun Luo, Stanislaus Antony Ceasar, Karim Benabdellah Published: 2025 Genome editing is a rapidly evolving field in which scientists alter the DNA of living organisms, by adding, removing, or modifying specific sequences, with the aim of altering gene expression and products to influence traits. Over the last three decades, several breakthroughs have been achieved in understanding the information encoded by the genome and in the tools available for genetic modification. In this Collection in BMC Biology, we aim to support the future developments of new and improved genome editing tools and associated technologies, as well as advancements in their application demonstrating broader adoption by the scientific community. Before the mid-1990s, genetic modification tools were largely dependent on laborious and time-consuming techniques including random mutagenesis, transgenesis, and gene targeting with homologous recombination vectors. Zinc finger nuclease (ZFN)-based genome editing was described in 1996 [1], based on engineering a pair of recombinant zinc finger nucleases, which consist of a sequence-specific zinc finger protein fused to a DNA endonuclease (e.g., FokI as illustrated in Fig. 1a), leading to the first directed genome-edited organism, the fruit fly Drosophila melanogaster, in 2002 [2]. However, the adaptation and application of ZFN for genome editing by the scientific community was somewhat limited due to the technical complexity, limitations in target site selection, high cost, as well as frequent and problematic off-target effects.Fig. 1Trajectory of genome editing technology and themes included in this collection. a Number of articles published annually within the key work of ZFN (zinc finger nuclease), TALEN (transcription activator-like effector nuclease), and CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). The number of articles published is retrieved from PubMed (date: September 19, 2025). Graphical illustrations for CRISPR-Cas9, prime editing, base editing, TALEN, and ZFN gene editing technologies are illustrated with biorender.com. b Themes of genome editing (GE) included in this article collection published by BMC Biology. NHEJ, non-homologous end joining; HDR, homology-directed repair; ND, neurodegenerative. Some illustrative items in the figure were generated with BioRender.com with license for publication Trajectory of genome editing technology and themes included in this collection. a Number of articles published annually within the key work of ZFN (zinc finger nuclease), TALEN (transcription activator-like effector nuclease), and CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). The number of articles published is retrieved from PubMed (date: September 19, 2025). Graphical illustrations for CRISPR-Cas9, prime editing, base editing, TALEN, and ZFN gene editing technologies are illustrated with biorender.com. b Themes of genome editing (GE) included in this article collection published by BMC Biology. NHEJ, non-homologous end joining; HDR, homology-directed repair; ND, neurodegenerative. Some illustrative items in the figure were generated with BioRender.com with license for publication In 2009, research was published on the code of DNA recognition by transcription activator-like effectors (TALEs), leading to the development of TALENs for genome editing [3] by fusion of a TALE DNA-binding domain for targeted DNA recognition and FokI nuclease for DNA cleavage. Compared to ZFNs, the process of designing and engineering pairs of sequence-specific TALENs is simpler, with significant improvements for targeting any locus in the genome. The TALEN-based genome editing system was quickly adopted by the community, but similarly to ZFNs, it is dependent on protein-guided gene editing and, thus, is significantly limited by low multiplexity capacity, and difficulty in custom designing due to an exponential increase in the number of vectors required for engineering and delivery. Only a few years after TALENs were developed, CRISPR emerged as the leading tool for genome editing due to its simplicity and specificity, with the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier and Jennifer Doudna for their seminal contributions [4]. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) are sequences of DNA forming the adaptive immune system found in bacteria and archaea. By co-expressing the Cas9 protein and a small guide RNA (gRNA or sgRNA) in cells, the Cas9 protein can introduce a double-strand DNA break (DSB) at genomic loci harboring the same sequences as the spacer sequences of sgRNA and a canonical protospacer motif (PAM) recognized by the Cas9 protein. Classical CRISPR-Cas9 dependent genome editing relies on the endogenous DNA repair machinery to repair the DSBs caused by Cas9, mostly via the non-homologous end joining (NHEJ) mechanism, leading to the installation of small deletions or insertions (indels) in cells. CRISPR-based tools have since become dominant, with substantial decreases in the use of ZFNs and TALENs (Fig. 1a). However, concerns over unintended edits introduced by CRISPR-Cas9 have also been raised. The large size of the Cas9 protein additionally hinders its compatibility with many in vivo delivery methods, such as the Adeno-Associated Viral (AAV) vector. Several variants of engineered Cas proteins with reduced off-target effects and diverse editing applications are also now used, such as HiFi-Cas9, Cas12, Cas13, and Cas14. Furthermore, for some genome editing applications requiring the insertion of a gene-of-interest (such as CAR-T cell engineering), engineering promoters of specific genes, or site-specific correction and introduction of variants, the classical CRISPR-Cas9 technology is hampered by low efficiency. To overcome these challenges, even more precise and DSB-free genome editing technologies, such as base editing for single-nucleotide substitutions [5] and prime editing for DNA template-free substitutions [6] (Fig. 1a), insertions or deletions, and transcriptional regulators (CRISPRi and CRISPRa), have been developed, and the current explosion in the use of artificial intelligence (AI)-assisted protein design promises further advances in our ability to engineer novel genome editing tools and manipulate genome function. The development of such tools has gone hand-in-hand with advances in genome sequencing and increases in genomic data and genetic variants linked to distinct human diseases and quantitative traits in other species. The combination of genome editing technologies and understanding of genetic variants has led to several breakthroughs in their applications. The first CRISPR-based therapy for curing Beta Thalassemia and Sickle Cell Disease has been approved for entering the market in 2023 [7]. Genetically tailored pig organs (hearts and kidneys) have been successfully transplanted to patients and demonstrated to have life-supporting functions [8]. CRISPR has also been employed to advance immunotherapy approaches, such as the development of allogeneic CAR-T cells with reduced immunogenicity and enhanced therapeutic potential. The first personalized CRISPR-based therapy for carbamoyl phosphate synthetase 1 (CPS1) deficiency in infants was recently reported, with remarkably high efficiency, efficacy, and safety [9]. Despite the field’s progress, challenges in accessibility, affordability, and long-term safety remain to be addressed. Genome editing has similarly transformed agricultural biotechnology and plant molecular breeding from a gene-discovery discipline into a precision-engineering platform for sustainable agriculture [10]. CRISPR/Cas-mediated editing in many plants (Arabidopsis thaliana, rice, tobacco, and wheat) was independently reported in 2013, establishing precise, heritable, and multiplexed gene modification as a practical tool for crop research. Soon after, targeted editing enabled rapid generation of loss- and gain-of-function mutants for key agronomic traits, including yield, stress tolerance, and nutrient efficiency. Development of base and prime editors adapted for plants then allowed single-nucleotide precision without DSB. Beyond applications in therapy and plant agriculture, genome editing technologies are being explored in a spectrum of diverse areas, from synthetic biology and the generation of novel bio-compounds to ecological conservation and pest control. In this Collection, we welcome submission of research and methodology articles related to the five themes highlighted in Fig. 1b. The theme of technology development covers studies describing the engineering of new genome editing systems, variants with enhanced fidelity and efficiency, approaches for modulating the NHEJ and homology-directed repair processes to enhance genome editing efficiency, and evolving systems base editing, prime editing, epigenome editing, mitochondrial genome editing, as well as computational tools for design and analysis. The theme of functional genomics will primarily be focusing on high-throughput genome editing systems, such as CRISPR perturbation screening, for the understanding of gene functions and application in early drug target screening. Since genome editing technology has entered the era of applications, this collection consists of one theme for therapeutic applications and another theme for agriculture and food biotechnology. Studies demonstrating the cutting-edge application of genome editing technology are within the focus of these two themes. Finally, we have included a theme covering other newly evolving genome editing systems such as SeekRNA, CAST, and other novel RNA-guided systems. We look forward to reading submissions that demonstrate the important trajectory in both technical development and applications of genome editing technologies, and most importantly, facilitate the translation of genome editing technologies to benefit global health and sustainability.